Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We hypothesized that HIV-dolutegravir-resistance is more frequent when co-administered with nucleos(t)ides with shorter intracellular half-lives. Multivariable analysis of 183 viremic (≥200c/mL) participants from four cohorts (N=660 participants) found dolutegravir-resistance in 21 (11.5%). Dolutegravir-resistance was greater with dolutegravir+lamivudine+zidovudine/(one on stavudine) (OR=19.4, 95%CI 5.1-74.3) or dolutegravir+lamivudine+abacavir (OR=5.4, 95%CI 1.1-25.8), compared to dolutegravir+lamivudine+tenofovir.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/cid/ciaf481 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Microbiological and Clinical Epidemiology of Lomentospora prolificans infections.
Indian J Med Microbiol
September 2025
Department of Clinical Microbiology, Christian Medical College, Vellore,632004, Tamil Nadu. Electronic address:
Lomentospora prolificans (formerly Scedosporium prolificans) is an emerging fungal pathogen, affecting both immunocompromised and immunocompetent individuals. Treatment is difficult due to intrinsic resistance against multiple anti-fungal agents. We describe five patients with L.
View Article and Find Full Text PDFEpidemiology of tuberculosis in Minas Gerais, Brazil, between 2013 and 2023 and the impact of the COVID-19 pandemic.
Front Public Health
September 2025
Department of Pharmaceutical Sciences, Faculty of Pharmacy, Federal University of Juiz de Fora, Juiz de Fora, Brazil.
Background: Tuberculosis (TB), a disease caused by bacteria of the (MTC), is one of the oldest diseases in human history, and despite several global efforts to reduce case numbers, it remains one of the main causes of death worldwide due infectious agents. This study aimed to analyze the epidemiological trends of tuberculosis in Minas Gerais, Brazil, from 2013 to 2023, with emphasis on the impact of the COVID-19 pandemic on case notification.
Methods: Based on epidemiological data obtained from the DATASUS platform, spanning the period from 2013 to 2023, the number of cases, the distribution of confirmed cases by sex, race, education, age group, HIV co-infection and presence of comorbidities such as diabetes, and risk factors like smoking and alcoholism were evaluated.
Oral pre-exposure prophylaxis (PrEP) denotes an effective strategy to reduce the risk of HIV infection. However, many individuals encounter difficulties adhering to the once-daily regimen, which highlights the need for a broader portfolio of PrEP options. The novel HIV capsid inhibitor lenacapavir (LEN), when injected every six month, has shown potential in the recently completed clinical trials.
View Article and Find Full Text PDFBroadly neutralizing antibodies (bNAbs) show promise for HIV treatment and prevention, but are vulnerable to resistance evolution. Comprehensively understanding in vivo viral escape from individual bNAbs is necessary to design bNAb combinations that will provide durable responses. We characterize viral escape from two such bNAbs, 10-1074 and 3BNC117, using deep, longitudinal sequencing of full length HIV envelope (env) genes from study participants treated with bNAb monotherapy.
View Article and Find Full Text PDFPharmacogenetics of First-Line Antitubercular Drugs: An Update.
Ther Drug Monit
September 2025
Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy; and.
Background: Tuberculosis (TB) treatment relies on a prolonged first-line antibiotic regimen, including isoniazid, rifampicin (RF), ethambutol (EMB), and pyrazinamide.Pharmacogenetics plays a crucial role in optimizing TB treatment by addressing individual variability in drug metabolism and responses. Genetic polymorphisms can significantly affect pharmacokinetics and therapeutic outcomes.
View Article and Find Full Text PDF